Skip to main content

Yesterday, Feb. 3, 2016, 74 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $18.72 to $469,419,506.01.

Highlighted Stocks Traded by Insiders:

American Electric Power (AEP) - FREE Research Report

Nowell Lionel L Iii, who is Director at American Electric Power, sold 8,209 shares at $62.00 on Feb. 3, 2016. Following this transaction, the Director owned 0 shares meaning that the stake was reduced by 100% with the 8,209-share transaction.

The shares most recently traded at $62.98, up $0.98, or 1.56% since the insider transaction. Historical insider transactions for American Electric Power go as follows:

  • 4-Week # shares sold: 1,273
  • 12-Week # shares sold: 1,273
  • 24-Week # shares sold: 1,273

The average volume for American Electric Power has been 3.3 million shares per day over the past 30 days. American Electric Power has a market cap of $30.4 billion and is part of the utilities sector and utilities industry. Shares are up 8.65% year-to-date as of the close of trading on Wednesday.

American Electric Power Company, Inc., a public utility holding company, engages in the generation, transmission, and distribution of electricity for sale to retail and wholesale customers. The stock currently has a dividend yield of 3.61%. The company has a P/E ratio of 16.8. Currently, there are 9 analysts who rate American Electric Power a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AEP - FREE

TheStreet Quant Ratings

rates American Electric Power as a

buy

. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, compelling growth in net income, good cash flow from operations, notable return on equity and reasonable valuation levels. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full

American Electric Power Ratings Report

TheStreet Recommends

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

John B Sanfilippo & Son (JBSS) - FREE Research Report

Pellegrino Frank S, who is Sr. Vice President at John B Sanfilippo & Son, sold 1,250 shares at $64.25 on Feb. 3, 2016. Following this transaction, the Sr. Vice President owned 18,203 shares meaning that the stake was reduced by 6.43% with the 1,250-share transaction.

Taaffe Ellen, who is Director at John B Sanfilippo & Son, sold 1,622 shares at $63.26 on Feb. 3, 2016. Following this transaction, the Director owned 12,021 shares meaning that the stake was reduced by 11.89% with the 1,622-share transaction.

The shares most recently traded at $64.81, up $1.55, or 2.39% since the insider transaction. Historical insider transactions for John B Sanfilippo & Son go as follows:

  • 4-Week # shares sold: 3,000
  • 12-Week # shares sold: 3,000
  • 24-Week # shares sold: 3,000

The average volume for John B Sanfilippo & Son has been 76,400 shares per day over the past 30 days. John B Sanfilippo & Son has a market cap of $546.0 million and is part of the consumer goods sector and food & beverage industry. Shares are up 17.58% year-to-date as of the close of trading on Wednesday.

John B. Sanfilippo & Son, Inc., together with its subsidiaries, processes and distributes peanuts and tree nut products in the United States. The company has a P/E ratio of 20.5. Currently, there are no analysts who rate John B Sanfilippo & Son a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on JBSS - FREE

TheStreet Quant Ratings

rates John B Sanfilippo & Son as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, reasonable valuation levels and good cash flow from operations. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full

John B Sanfilippo & Son Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

ARIAD Pharmaceuticals (ARIA) - FREE Research Report

Panayiotopoulos Paris, who is President and CEO at ARIAD Pharmaceuticals, bought 61,099 shares at $4.91 on Feb. 3, 2016. Following this transaction, the President and CEO owned 61,099 shares meaning that the stake was boosted by 100% with the 61,099-share transaction.

The shares most recently traded at $5.05, up $0.14, or 2.77% since the insider transaction. Historical insider transactions for ARIAD Pharmaceuticals go as follows:

  • 4-Week # shares sold: 2,696
  • 12-Week # shares sold: 2,696
  • 24-Week # shares sold: 36,822

The average volume for ARIAD Pharmaceuticals has been 3.4 million shares per day over the past 30 days. ARIAD Pharmaceuticals has a market cap of $946.5 million and is part of the health care sector and drugs industry. Shares are down 19.04% year-to-date as of the close of trading on Wednesday.

ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of medicines for cancer patients. Currently, there are 2 analysts who rate ARIAD Pharmaceuticals a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ARIA - FREE

TheStreet Quant Ratings

rates ARIAD Pharmaceuticals as a

sell

. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full

ARIAD Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.